What Tilade Treats: Main Uses and Benefits

The medication is generally used for maintenance therapy in conditions characterized by periods of heightened symptoms, such as mild to moderate persistent bronchial asthma in both adult and pediatric patients. This supportive treatment contributes to improved day-to-day comfort and is relevant for conditions associated with inflammatory or irritative processes. Indications include bronchial asthma, exercise-induced bronchospasm, and allergic conjunctivitis. The medication assists with managing symptoms related to heightened physiological activity.

“This preventative strategy helps address symptom clusters that may become intense or disruptive.”

The medication is also commonly used when supportive symptom management is appropriate to help prevent breathing difficulties caused by exposure to cold air or specific inhaled allergens. For the eyes, it is applied across domains where additional symptomatic support is needed; it may assist with easing ocular itching and watering associated with allergic conjunctivitis. This use helps ease the overall symptom burden and may assist with maintaining functional stability during symptomatic phases.

---

Quick Fact: Supports management of Recurrent Wheezing

Regulatory References

1. Irish Health Products Regulatory Authority (HPRA) document

Official Eligibility and Contraindications for Tilade (Nedocromil Sodium)

The ability to use Tilade is strictly defined by regulatory labeling based on patient characteristics and the nature of the condition being treated.

---

Populations for Whom Use is Contraindicated

Use of Tilade is contraindicated for individuals with known hypersensitivity or allergy to Nedocromil Sodium or to any excipient in the preparation. The medicine must not be used for the reversal of acute bronchospasm or for emergencies like status asthmaticus, as it is a preventative treatment only.

Age-Related Eligibility

Preparation	Age Group Eligibility	Regulatory Status
Inhalation Aerosol	Children under 6 years	Use not established
Inhalation Aerosol	Adults and Children 6+	Eligible for maintenance therapy
Ophthalmic Solution	Children under 3 years	Use not established

Pregnancy and Lactation Status

Tilade is assigned Pregnancy Category B by the FDA. Regulatory guidelines state that use during pregnancy is conditional and should occur only if clearly needed. Due to limited data on excretion into human milk, caution is advised when administering the drug to a nursing woman. The product label does not specify restrictions based on hepatic or renal impairment.

Interactions with other medicines and products

Official Regulatory Interaction Profile

The interaction profile of Tilade, which contains Nedocromil Sodium, is largely defined by its unique pharmacokinetic properties. Due to low systemic absorption following inhalation, the medicine is minimally present in the bloodstream and is not metabolized by the liver in humans. This profile leads to the regulatory finding that there are no known significant drug interactions with other systemically administered medicinal products. Official prescribing information confirms that the lack of metabolism negates the risk of pharmacokinetic interactions, such as those mediated by Cytochrome P450 (CYP) enzymes.

Interaction Type	Regulatory Status	Constraint Details
Systemic Drug-Drug	No known significant interactions	No prohibitions or restrictions documented with other systemic medicines.
Metabolic (CYP)	None documented	Lack of human metabolism eliminates CYP enzyme-related interaction risk.
Timing Requirements	Mandatory administration rule	An inhaled bronchodilator must be administered prior to Nedocromil Sodium.

This minimal systemic interaction risk is consistently stated across major regulatory documents. Nedocromil Sodium has been safely co-administered with other standard anti-asthma treatments, including inhaled corticosteroids and oral and inhaled bronchodilators, without evidence of increased frequency of adverse events. The one mandatory constraint relates only to the sequencing of administration for co-delivered inhaled products, ensuring optimal drug delivery to the airways.

Tilade (nedocromil) is a chromone derivative that acts as a mast cell stabilizer and inflammatory cell modulator. The molecule is primarily delivered to and accumulates in the bronchial mucosa and airway lumen, targeting resident inflammatory cells, including mast cells, eosinophils, neutrophils, and macrophages.

Its main interaction is as an inhibitor of the activation of these inflammatory cells. Nedocromil modulates intracellular signaling pathways by interfering with the calcium-dependent cascade necessary for degranulation and mediator release. Specifically, it inhibits the influx of calcium ions into the cell cytoplasm, which is a critical step for vesicle fusion and the exocytosis of pre-formed inflammatory mediators.

Downstream consequences include the non-release of a broad spectrum of inflammatory molecules, such as histamine, leukotrienes (e.g., LTC4), and prostaglandins ( PGD2). This suppression of cellular activation and mediator release results in a system-level physiological modulation characterized by a decrease in local inflammatory processes within the respiratory tract.

The medicine Nedocromil Sodium is utilized through two distinct administration methods: oral inhalation via a Metered-Dose Inhaler (MDI) for long-term management, and topical ophthalmic instillation for localized conditions. The product is designated exclusively for prophylactic use, meaning it must be administered on a consistent schedule to achieve continuous control and is not indicated for the immediate relief of acute episodes.

Administration Regimens

Application	Standard Dosing and Frequency
Inhalation (MDI)	Two actuations per dose, administered four times daily (QID) at regular intervals.
Ophthalmic Solution	One drop per affected eye per dose. Typically administered four times daily (QID).

For inhalation therapy, the standard adult regimen is applied to pediatric patients 6 years of age and older. The dosing frequency may be reduced to two or three times daily only after the condition is brought under satisfactory control.

Before initial use, or if the device has been unused for a defined period, the MDI requires a mandated priming procedure (e.g., three test sprays) to ensure the proper metered dose is delivered upon administration. Furthermore, obtaining the full preventative benefit of the medication requires continuous, long-term use for one week or longer following initiation of the prescribed regimen. When utilizing the ophthalmic solution, contact lenses must be removed prior to instillation and not reinserted for a period of at least fifteen minutes.

Research evidence / Overview of studies for Tilade

Evidence for use in Bronchial Asthma (Mild to Moderate Persistent)

This section summarizes the research base for Tilade in maintenance asthma therapy, summarizing the Randomized Controlled Trials (RCTs) and meta-analyses that focused on changes in patient symptoms, lung function metrics, and the use of rescue inhalers across adult and pediatric groups.

Research explored this medicine for conditions characterized by fluctuating manifestations. Studies monitored objective functional measures, including the ability of patients to forcefully exhale air from their lungs (Forced Expiratory Volume in 1 second, or FEV1). Findings describe patterns observed in the studies where some trials reported measurements of reduced need for rescue inhalers over the short-term study period. However, the data show patterns related to objective lung function changes (FEV1) that were variable across different trials. This reflects the finding that studies reported variability when measuring these specific physiological outcomes.

---

Evidence for use in Exercise-Induced Bronchospasm (EIB)

This part of the overview describes the research designed to evaluate outcomes on lung function and symptoms following standardized exercise tests. Research examined Tilade in research contexts involving episodic or acute changes where subjects with confirmed EIB were given the medicine shortly before performing a controlled exercise test. The central outcome that was evaluated in these acute trials was the degree of observed change in the maximum fall in lung function (FEV1) following the challenge.

Findings describe a consistent pattern of observed changes in the magnitude of the fall in lung function when the medicine was studied in the tested populations immediately before exercise. Evidence for this acute use was noted as generally reproducible across the studied trials. However, this evidence is specific to acute, single-dose prevention.

---

Evidence Gaps and Areas of Uncertainty

This final part clarifies what remains unclear within the regulatory research record. Comparative evidence is lacking for a definitive assessment of Tilade's effect against all established standard-of-care treatments, particularly over long periods. Also, follow-up durations were limited in many of the primary efficacy studies, meaning there is limited information for long-term outcomes regarding the drug’s sustained effect on disease progression. Data for certain groups, like those with severe, unstable asthma, remain limited.

Key Studies & References

1. Nedocromil Inhalation, U.S. National Library of Medicine (NIH) MedlinePlus Drug Information
2. Tilade License Summary of Product Characteristics (SPC) - Irish Health Products Regulatory Authority (HPRA)
3. Nedocromil sodium (Tilade): mechanism of action and clinical uses - NIH PubMed Central Review

Common questions about Tilade (FAQ)

Q: What is the specific dose strength per puff for the Nedocromil Sodium Inhalation Aerosol?

A: According to the official product information, the metered-dose inhaler (MDI) delivers a specific amount of the active ingredient. Each full actuation (puff) provides 1.75 mg of nedocromil sodium. This dose is intended to ensure the appropriate amount of medicine reaches the airways for prophylactic use.

Q: Can this medicine cause a sore throat or throat irritation?

A: Official product documents indicate that cough and throat irritation have been reported as respiratory side effects. These effects were noted in a small percentage of patients (6-7%) during clinical data collection. Drinking water before and after inhalation may help relieve this irritation.

Q: Can Nedocromil Sodium cause dry mouth?

A: Dry mouth is listed as a possible adverse effect in official regulatory documents. If this occurs, it is one of the documented reactions that patients may experience while using the medication.

Q: Are there any long-term safety concerns with using Nedocromil Sodium?

A: Evidence indicates that nedocromil sodium has low systemic absorption, meaning very little of the drug enters the general bloodstream. Non-clinical studies found no evidence of carcinogenic potential or impairment of fertility. This profile is consistent with the drug’s role as a non-systemic prophylactic agent.

Q: Does Nedocromil Sodium make you feel jittery or anxious?

A: While the official label categorizes headache and dizziness as possible nervous system side effects, it does not specifically list terms like 'jittery' or 'anxious' as common reactions. Any concerns about changes in behavior or mood are best discussed with a healthcare professional.

Q: Can I take Nedocromil Sodium with food or dietary supplements?

A: Official drug labeling indicates there is no sufficient scientific evidence regarding the use and safety of Nedocromil with any particular food or dietary supplement. The minimal systemic absorption is consistent with the lack of definitive regulatory information regarding food or supplement interactions.

Q: Can I consume alcohol while using Nedocromil Sodium?

A: Official warnings describe that alcohol intake is advised against for patients, particularly those with underlying liver disorder or liver dysfunction.

Q: Can the elderly use this medication safely?

A: Regulatory documents reviewed for use in older patients indicate that no overall differences in safety or effectiveness have been observed when compared to younger adult patients.

Q: Was this product tested against a placebo?

A: Yes, the effectiveness of the medication was examined in a clinical trial that was double-blind and placebo-controlled. This research method is utilized to evaluate the drug's effects against an inactive substance.

Q: What should I do if I miss a dose?

A: If a regular dose is missed, official patient information advises against taking extra medicine to make up for the missed dose. The guidance is to take the next scheduled dose at the usual time and then resume the normal routine.

Q: What is the maximum daily dosage?

A: Official guidance states that the maximum recommended dosage should not be exceeded. The standard regimen is two puffs four times a day, which defines the typical maximum intended amount for daily use.

Q: Do I need to shake the inhaler before use?

A: Yes, patient instructions for the Metered-Dose Inhaler (MDI) generally advise shaking the inhaler well before each use. This step ensures that the medication is properly mixed and prepared for optimal delivery.

Q: Do I need to rinse my mouth after use?

A: Rinsing the mouth is not a specified requirement in the product labeling. However, some official sources suggest that drinking water before and after inhalation may help to relieve throat irritation if it occurs.

Q: Is Nedocromil Sodium a controlled substance?

A: According to official regulatory status classifications, nedocromil sodium is not listed as a controlled substance. It is designated as a prescription-only medicine (Rx).

Q: What is the correct inhaler technique?

A: To optimize the drug's effect, it is important to ensure the proper dose reaches the lungs. Therefore, patients must be properly instructed in the correct method of use as outlined in the manufacturer’s patient information.

Q: What happens if I take too much (overdose)?

A: Official regulatory sources report that no overdose cases have been noted in human studies for nedocromil sodium. The regulatory warning states that excessive inhalation of the aerosol should be avoided because large doses of the propellants may be hazardous.

Q: Is there a generic version of Nedocromil Sodium available?

A: Nedocromil is the generic name for the active ingredient in this medicine. This means the substance is often referred to by this generic name in regulatory and medical circles.

Q: What should I look out for if my asthma symptoms get worse after starting this medication?

A: If symptoms do not improve or the patient's condition worsens while using the medication, the regulatory instruction specifies not to increase the dosage, and instead to notify the prescribing physician immediately.

Q: Can I use this medicine for a non-asthma cough?

A: Nedocromil inhalation is approved solely for the prevention of asthma and bronchospasm. Its efficacy has not been investigated for managing other conditions, such as chronic obstructive pulmonary disease (COPD) or non-specific cough.

Q: What is the purpose of the propellant in the inhaler?

A: The inhalation aerosol requires a propellant for the correct delivery of the medicine into the airways. Regulatory documents include a warning that excessive inhalation of propellants may be hazardous.

Q: What is the expiration date on the inhaler based on?

A: The expiration date is a safety measure determined by the manufacturer based on stability testing data. This date is verified by regulatory bodies to ensure the medicine retains its required strength, quality, and purity throughout its shelf life.

The storage and disposal of Tilade (nedocromil sodium) Inhaler must follow strict regulatory requirements due to its nature as a pressurized container.

Item	Requirement/Classification
Labeled storage temperature requirements:	Store between 2 C and 30 C (36 F and 86 F).
Prohibited Storage:	Do not freeze; avoid exposure to temperatures above 120 F.
Child-protection storage requirements:	Keep the medication out of the reach of children.
Stability-linked discard limit:	Discard the unit after 104 metered actuations, as the delivered dose may become inconsistent after this point.
Handling and Packaging rules:	The canister contents are under pressure; do not puncture the canister. Reprime the inhaler with three test sprays if unused for more than seven days.
Official disposal rules:	Never throw the canister into a fire or incinerator. Disposal of the canister and any unused product must comply with local regulations and laws.

Regulatory documents define the storage profile by specifying temperature boundaries and safety constraints related to the pressurized form. The discard limit and repriming rule are stability requirements that ensure consistent medication delivery.